The global enteral nutrition market was valued at $12,300.0 million in 2015, and it is expected to grow at a CAGR of 5.8% during 2016 - 2022. The factors driving the growth of the global market include increasing geriatric population, lower cost of enteral nutrition products, surge in the number of victims of malnutrition receiving treatment, high number of premature births and increasing incidence of cancer and central nervous system diseases. Enteral nutrition products are considered to be one of the best alternatives during the treatment of cancer and CNS diseases, to avoid nutrition deficiency in human body for optimal functioning of various organs.

Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/enteral-nutrition-market/report-sample

According to the WHO, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 globally. The organization also reported that 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.

Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/enteral-nutrition-market

In 2015, Asia-Pacific held the largest share in the global enteral nutrition market with 34.1% share. The enteral nutrition market in the region is anticipated to witness the highest growth at a CAGR of 7.0% during the forecast period. The increasing birth rate, along with growing geriatric population and high number of people having malnutrition is driving the growth of the enteral nutrition market in the region.

Some of the major players operating in the global enteral nutrition market include Baxter International Inc., Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A., Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, and Perrigo Company Plc.